Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

NCT ID: NCT05803785

Last Updated: 2025-07-08

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-10-31
• Study Completion Date: 2026-03-31

Brief Summary

This open-label study is being conducted to evaluate the initial safety and tolerability of BBC1501 IVT in patients with nAMD. The primary objective of this study is to evaluate the safety and tolerability of 3 ascending doses of IVT BBC1501 in patients with nAMD. The secondary objective of this study is to exploratory of BBC1501 efficacy following 3 ascending dose of BBC1501 in nAMD patient.

Conditions

Age-Related Macular Degeneration

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BBC1501 1.25ug

Cohort 1; open-label, non-randomized, single administration

Group Type: EXPERIMENTAL

BBC1501

Intervention Type: DRUG

BBC1501 solution for Intravitreal injection

BBC1501 2.5ug

Cohort 2; open-label, non-randomized, single administration

Group Type: EXPERIMENTAL

BBC1501

Intervention Type: DRUG

BBC1501 solution for Intravitreal injection

BBC1501 5ug

Cohort 3; open-label, non-randomized, single administration

Group Type: EXPERIMENTAL

BBC1501

Intervention Type: DRUG

BBC1501 solution for Intravitreal injection

Interventions

BBC1501

BBC1501 solution for Intravitreal injection

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Able to provide voluntary written informed consent on the approved ICF, understand the study requirements, and are willing to follow and complete all the study required procedures.
• Male or female aged ≥ 50 years.
• Participants who as per investigator's judgements are non-responders to at least 2 prior anti-VEGF treatment for nAMD in the study eye
• Active CNV lesions, secondary to nAMD as confirmed with SD-OCT (or SS-OCT), FFA and fundus photography (FP) in the study eye.
• Best corrected visual acuity (BCVA) between 60 and 21 letters, inclusive, in the study eye using ETDRS testing or BCVA between 20/60 and 20/400 letters, inclusive, in the study eye by Snellen chart
• Participant has CST of at least 300 uM with presence of intraretinal and/or subretinal fluid
• Participants who have had a washout period of at least six weeks prior to first administration of the IMP for any IVT anti-VEGF medication and, who in the opinion of the investigator, have disease sufficiently stable to enable this interval.

Exclusion Criteria

• Use of any of the following treatments or anticipated use of any of the following treatments to the study eye:
• Intravitreal or periocular corticosteroid, within 90 days prior to Visit 1 (Day 1) and throughout the study.
• Glaucoma, evidenced by an IOP of > 21 mmHg, or chronic hypotony (< 6 mmHg) in the study eye.
• Evidence of any other ocular disease other than nAMD in the study eye that may confound the outcome of the study (eg, active diabetic retinopathy, posterior uveitis, pseudovitelliform macular degeneration, moderate/severe myopia).
• Participants with advanced nAMD and no prognosis of BCVA as per Investigator's judgement (e.g. due to macular OCT signs of atrophy or photoreceptors disruption, or macular/foveal subretinal hemorrhage).
• Need for ocular surgery in the study eye during the course of the study.
• YAG laser capsulotomy within 30 days prior to Visit 1 (Day 1) in the study eye.
• Intraocular surgery, including lens removal or laser, within 90 days prior to Visit 1 (Day 1) in the study eye.
• Ocular or periocular infection in either eye.
• Pupillary dilation inadequate for quality stereoscopic fundus photography in the study eye.
• Media opacity that would limit clinical visualization, intravenous fluorescein angiography, or spectral-domain optical coherence tomography (SD-OCT) evaluation in the study eye.
• History of herpetic infection in the study eye or adnexa.
• Presence of known active toxoplasmosis, inactive toxoplasmosis or toxoplasmosis scar in either eye.
• Presence of any form of ocular malignancy including choroidal melanoma in either eye

• Minimum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Benobio Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Inhyun Lee, ph.D

Role: STUDY_CHAIR

Benobio Co., Ltd.

Locations

Benobio Investigational site

Sydney, New South Wales, Australia

Site Status: NOT_YET_RECRUITING

Sydney Hospital

Sydney, , Australia

Site Status: RECRUITING

Countries

Australia

Central Contacts

jihye choe

Role: CONTACT

jihye.choe@benobio.com

+827046675278

Facility Contacts

jihye choe

Role: primary

jihye.choe@benobio.com

Other Identifiers

BBRP11001-101

Identifier Type: -

Identifier Source: org_study_id